Aerie Pharma submits U.S. application for eye drop Roclatan

|About: Aerie Pharmaceuticals,... (AERI)|By:, SA News Editor

Aerie Pharmaceuticals (NASDAQ:AERI) has filed a marketing application with the FDA seeking approval for Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a once-daily eyedrop to reduce intraocular pressure in patients with glaucoma or ocular hypertension.

Roclatan is a fixed-dose combination of Rhopressa and latanoprost, a prostaglandin analog.

The company expects a 10-month review cycle.

Subscribe for full text news in your inbox